Grown Rogue Reports Q1 2026 Results: 28% Revenue Growth, New Jersey Expansion, Updated Guidance for Cannabis Markets
Minichart
Last updated: May 13, 2026
Celularity has finalized the sale of its asset portfolio to NexGel for $13.3 million. This strategic divestment is intended to sharpen Celularity's focus on its core longevity therapeutics business and improve its financial standing.
- The transaction involves the transfer of Celularity's placental allogeneic cell therapy assets, intellectual property, and related infrastructure to NexGel. This sale represents a significant step in Celularity's plan to streamline operations and concentrate on its promising pipeline of longevity treatments.
- The $13.3 million in proceeds will bolster Celularity's balance sheet, providing enhanced financial flexibility for ongoing research, development, and commercialization efforts. This includes advancing its lead therapeutic programs aimed at addressing age-related diseases and improving human healthspan.
- Celularity's strategic pivot is designed to accelerate the development and market entry of its innovative longevity therapies, which target a range of age-related conditions. The company maintains that this sale will not impede its progress in its primary therapeutic areas.
- This asset sale is a key component of Celularity's broader strategy to optimize its business model and maximize shareholder value by concentrating on its most impactful scientific advancements in the rapidly growing field of longevity.
